Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma|
|Citation:||British Journal of Haematology, 2013; 161(4):499-507|
|Publisher:||Blackwell Publishing Ltd|
|Kate Vandyke, Annie W.S. Chow, Sharon A. Williams, Luen B. To and Andrew C.W. Zannettino|
|Abstract:||N-cadherin (cadherin 2, type 1, N-cadherin (neuronal); CDN2) is a homotypic adhesion molecule that is upregulated in breast, prostate and bladder cancer. Here we investigated the prognostic significance of upregulated N-cadherin expression in multiple myeloma (MM). Our results indicate that N-cadherin protein and gene expression is abnormally increased in trephine biopsies and CD38⁺⁺/CD138⁺ plasma cells from MM patients, when compared with those of normal donors. In addition, levels of circulating N-cadherin were elevated in a subset of patients with MM (n = 81; mean: 14·50 ng/ml, range: 0–146·78 ng/ml), relative to age-matched controls (n = 27; mean: 2·66 ng/ml, range: 0–5·96 ng/ml), although this did not reach statistical significance. Notably, patients with abnormally high levels of N-cadherin (>6 ng/ml) had decreased progression-free survival (P = 0·036; hazard ratio: 1·94) and overall survival (P = 0·002; hazard ratio: 3·15), when compared with patients with normal N-cadherin levels (≤6 ng/ml). Furthermore, multivariate analyses revealed that the combination of N-cadherin levels and International Staging System (ISS) was a more powerful prognostic indicator than using ISS alone. Collectively, our studies demonstrate that circulating N-cadherin levels are a viable prognostic marker for high-risk MM patients.|
|Keywords:||multiple myeloma; N-cadherin; prognostic marker, novel therapeutic target, ISS|
|Rights:||© 2013 John Wiley & Sons Ltd|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.